Nanomedicine (London, England)最新文献

An overview of strategies and challenges adopted to silence BCR-ABL gene by small interfering RNA. 小干扰RNA沉默BCR-ABL基因的策略和挑战综述。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-11 DOI: 10.1080/17435889.2025.2571019

Laura Fancello, Maria Manconi, Maria Letizia Manca

{"title":"An overview of strategies and challenges adopted to silence BCR-ABL gene by small interfering RNA.","authors":"Laura Fancello, Maria Manconi, Maria Letizia Manca","doi":"10.1080/17435889.2025.2571019","DOIUrl":"https://doi.org/10.1080/17435889.2025.2571019","url":null,"abstract":"BCR-ABL oncogene associated with chronic myeloid leukemia (CML) encodes for tyrosine kinase with enhanced activity that drives the uncontrolled proliferation of white blood cells. The therapy with tyrosine kinase inhibitors improves the life expectancy of patients without curative effects. However, lifelong treatments are required and usually associated with adverse effects and drug resistance. Alternatively, gene-silencing using nucleic acids has been proposed to avoid the synthesis of protein kinase. The use of RNA Interference seems to be the most promising strategy for new therapy. This review provides an overview of clinically used therapy with tyrosine kinase inhibitors and explores future advances using RNA interference, especially siRNA, as it is the one tested the most up to now. The studies reporting the use of siRNA to silence BCR-ABL gene are analyzed based on the used sequence, chemical modifications, and delivery systems. The sequence that targets specific regions of BCR-ABL gene and chemical modifications that improve stability, specificity, and potency are underlined. Finally, the studies devoted to delivering siRNA have been examined based on the vector nature (natural or synthetic) and delivery mechanism (conjugation or loading). The level of maturity reached (in vitro, in vivo, pre-clinical) in the studies has been underlined. No clinical studies were found.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-20"},"PeriodicalIF":3.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment. 纳米颗粒介导的siRNA递送在乳腺癌治疗中的突破。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-09 DOI: 10.1080/17435889.2025.2567842

Davi Trombini Aleixo, Estael L C Cruz-Cazarim, Kezia C B Ferreira, Lívia N Grossi, Wilson R Braz, Natália P Silva, Fábio Pittella-Silva, Marina F Dias, Silvia L Fialho, Guilherme D Tavares, Frederico Pittella

{"title":"Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment.","authors":"Davi Trombini Aleixo, Estael L C Cruz-Cazarim, Kezia C B Ferreira, Lívia N Grossi, Wilson R Braz, Natália P Silva, Fábio Pittella-Silva, Marina F Dias, Silvia L Fialho, Guilherme D Tavares, Frederico Pittella","doi":"10.1080/17435889.2025.2567842","DOIUrl":"https://doi.org/10.1080/17435889.2025.2567842","url":null,"abstract":"Although breast cancer treatments have improved, challenges like tumor heterogeneity and drug resistance remain. RNA interference (RNAi), especially through small interfering RNA (siRNA), is a promising strategy to silence specific genes and improve clinical outcomes. However, the clinical translation of siRNA has been limited by barriers related to stability, biodistribution, cellular uptake, among others. Nanoparticle-based delivery systems have emerged as transformative platforms to address these limitations, enhancing siRNA protection, targeting, and intracellular release. This review discusses the major breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer treatment, focusing on how innovations in nanocarrier design have enhanced siRNA stability, targeting, and therapeutic efficacy. We highlight key characteristics in RNA interference mechanisms, the evolution of computational tools for optimizing siRNA design, and the approval of RNAi-based therapies that laid the foundation for oncologic applications. Special emphasis is given to the development of lipid, polymeric, and inorganic nanoparticles engineered for efficient siRNA delivery, their role in overcoming drug resistance when combined with conventional therapies, and the current progress of clinical trials against solid tumors. By integrating nanotechnology and RNAi, these breakthroughs offer new opportunities for precise, durable, and personalized strategies in breast cancer treatment, with the potential to transform the current therapeutic landscape.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-25"},"PeriodicalIF":3.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomaterials and nanotechnology in otolaryngology: a narrative review. 纳米材料和纳米技术在耳鼻喉科：叙述回顾。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-08 DOI: 10.1080/17435889.2025.2570706

Nuray Bayar Muluk, Cemal Cingi

{"title":"Nanomaterials and nanotechnology in otolaryngology: a narrative review.","authors":"Nuray Bayar Muluk, Cemal Cingi","doi":"10.1080/17435889.2025.2570706","DOIUrl":"https://doi.org/10.1080/17435889.2025.2570706","url":null,"abstract":"We reviewed usage of nanomaterials and nanotechnology in otolaryngology. The literature search in this narrative review used Google, Google Scholar, PubMed, EBSCO, Proquest Central, Proquest Central, Web of Science and Scopus at Kırıkkale University. We searched for \"Nanomaterials,\" \"nanotechnology,\" \"otolaryngology,\" \"rhinology,\" \"laryngology,\" \"head and neck,\" and \"otology\" between 2020 and 2025. Clinical trials, retrospective studies, reviews and experimental studies were included into this paper. Nanomaterials and nanoparticles (NPs) have the potential to transform medical care. NPs can bypass traditional therapeutic barriers because of their small size. Potential applications of nanoparticles include drug delivery and cell-to-cell communication. In rhinology, Amphotericin B was delivered using gelatine nanoparticles without significant nephrotoxicity or hematological side effects. In cases ranging from obvious vascular bleeding to cerebral hemorrhage, N-hydroxysulfosuccinimide formed a nanofiber barrier that achieved rapid and complete hemostasis. In medical nanotechnology, cancer theranostics is currently a leading field. In otology, nanotechnology is used for the cochlear implant. Creating nanofibrous scaffolds with synthetic, biomimetic extracellular matrix analogs holds great promise for regenerative medicine. Advantages of nanotechnology over conventional methods are targeted delivery, reduced side effects, biosafety and scalable production in the fields of rhinology, laryngology, head & neck, and otology.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Silver nanoparticles: a new frontier in ophthalmic innovation and treatment. 银纳米粒子：眼科创新和治疗的新前沿。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-08 DOI: 10.1080/17435889.2025.2571060

Tong Wang, Jian Cao, Fan Gan, Yupeng Zhang, Zhipeng You

引用次数: 0

Applying click chemistry principles to the design of tumor-targeted nanosystems. 将点击化学原理应用于肿瘤靶向纳米系统的设计。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-07 DOI: 10.1080/17435889.2025.2567837

J J Diaz-Mochon, R M Sanchez-Martin

引用次数: 0

Development and functional characterization of a tissue-engineered blood-air barrier model for in vitro applications. 用于体外应用的组织工程血气屏障模型的开发和功能表征。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1080/17435889.2025.2552101

Neval Sevinc Ozdemir, Simal Yaren Sahin, Halime Kenar, Vasif Hasirci

{"title":"Development and functional characterization of a tissue-engineered blood-air barrier model for in vitro applications.","authors":"Neval Sevinc Ozdemir, Simal Yaren Sahin, Halime Kenar, Vasif Hasirci","doi":"10.1080/17435889.2025.2552101","DOIUrl":"10.1080/17435889.2025.2552101","url":null,"abstract":"Background: The blood-air barrier (BAB) of the lung is a critical interface responsible for gas exchange and protection against external attempts, and acts as a selective barrier. Developing in vitro models that replicate its structural and functional properties is essential in studying pulmonary diseases and their therapy.Methods: In this study, a model consisting of alveolar epithelial (A549) and primary endothelial (pHUVEC) cells seeded on opposite sides of a thin (11 ± 4 μm), electrospun poly(ε-caprolactone) mesh of nanofibers (140-800 nm) to represent the basal membrane, and the interstitial matrix of the native BAB when coated with collagen type I, fibronectin, and laminin 511 proteins. The dense, nanofibrous architecture of the mesh enabled the formation of cellular monolayers on opposite sides, allowing gas and nutrient exchange for 14 days at air-liquid interface.Results: The mesh had a Young's modulus of 8.0 ± 0.8 MPa, and upon coating with proteins, the water contact angles were decreased from 127.5°±2.6 to 94.4°±3.6. Epithelial and endothelial monolayers demonstrated tight junction formation as shown by ZO-1 and CD31 expression. TEER was measured as 44 ± 5.0 Ω·cm2 with a permeability coefficient (Papp) of 2-5 × 10-6 cm/s against fluorescein.Conclusion: This study presents a physiologically relevant in vitro BAB model for respiratory research and therapies.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2511-2522"},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the action mechanisms and safety of nanoparticles with functional toxicogenomics. 用功能毒物基因组学研究纳米颗粒的作用机制和安全性。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-01 Epub Date: 2025-06-26 DOI: 10.1080/17435889.2025.2523733

Buerlan Yeerkenbieke, Yanchen Li, Fabian Kiessling, Twan Lammers, Christopher Vulpe, Roger M Pallares

引用次数: 0

Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications. rombus形状的α-Fe₂O₃纳米颗粒用于抗菌和抗癌。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-01 Epub Date: 2025-08-11 DOI: 10.1080/17435889.2025.2542716

Sakshi Bajhal, Nishakavya Saravanan, Anandhakumar Sundaramurthy

{"title":"Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications.","authors":"Sakshi Bajhal, Nishakavya Saravanan, Anandhakumar Sundaramurthy","doi":"10.1080/17435889.2025.2542716","DOIUrl":"10.1080/17435889.2025.2542716","url":null,"abstract":"Background: The increasing incidence of bacterial infections in cancer patients, combined with the growing limitations of conventional antibiotics such as poor site-specific targeting and antibiotic resistance, necessitates the development of advanced therapeutic strategies.Methodology: Rhombus-shaped α-Fe₂O₃ nanoparticles (NPs) were synthesized via hydrothermal route and characterized for their structural, optical, and morphological properties. Lymecycline was encapsulated into NPs, and its pH-dependent release was assessed. Antibacterial activity was evaluated using the well diffusion and minimum inhibitory concentration assay, while anticancer potential was examined using AlamarBlue and cytotoxicity assays against THP-1 cells. Biocompatibility was assessed using normal L-929 fibroblast cells.Results: The synthesized Fe₂O₃ NPs measured ~80 to 150 nm in length and ~50 nm in width. Lymecycline-loaded NPs demonstrated pH-responsive release, with 60% drug release at pH 5.5 and 43% at pH 7.4. They exhibited enhanced cytotoxicity (72%) against THP-1 cancer cells, while showing good biocompatibility with L-929 normal cells. Additionally, strong antibacterial activity was observed against Escherichia coli and Staphylococcus aureus.Conclusions: Lymecycline-loaded α-Fe₂O₃ NPs exhibited pH-responsive drug release, selective cytotoxicity toward THP-1 cancer cells, strong antibacterial efficacy, and good biocompatibility with normal cells. These findings highlight their dual functionality and potential as a promising nanoplatform for future anticancer and antimicrobial therapies.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2411-2423"},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice. cergenin包覆金属纳米颗粒的生物学特性-临床实践的未来挑战和前景。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/17435889.2025.2554559

Piotr Bijak, Ewelina Piktel, Wiesława Niklinska, Tamara Daniluk, Paulina Paprocka, Grzegorz Król, Paul B Savage, Robert Bucki

{"title":"Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice.","authors":"Piotr Bijak, Ewelina Piktel, Wiesława Niklinska, Tamara Daniluk, Paulina Paprocka, Grzegorz Król, Paul B Savage, Robert Bucki","doi":"10.1080/17435889.2025.2554559","DOIUrl":"10.1080/17435889.2025.2554559","url":null,"abstract":"Considering the priority of searching for new therapeutic strategies related to increasing microbial resistance and complex needs of oncological treatment, the potential of ceragenin-coated metal nanoparticles (primarily in the form of core-shell nanosystems) as tools for developing new treatment methods was discussed. In particular, the complex mechanisms of action of the ceragenin-containing nanosystems were described, and the presented actions were compared with the native efficacy of ceragenins. The methods for their synthesis and characterization, taking into account features such as size, shape, surface charge, and colloidal stability, were also presented. The synergy of this combination is a potentially effective alternative for combating multidrug-resistant strains of bacteria, as well as fungi. This is also crucial when counteracting the biofilms forming on the surfaces of implants, catheters, or endotracheal tubes. When applying for cancer therapies, the employment of modified ceragenin nanosystems as targeted drug delivery systems may help achieve higher drug concentrations in the tumor environment as well as lower systemic toxicity compared to current therapeutic methods. The collected data justify the need for further studies to fully assess the safety and therapeutic efficacy of ceragenin-containing nanosystems, which will certainly translate into the development of innovative therapeutic methods.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2523-2543"},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery. 新兴的脂质纳米颗粒系统能够有效地在肌肉内递送RNA。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-10-01 Epub Date: 2025-09-03 DOI: 10.1080/17435889.2025.2555507

Aun Raza, Runtong Zhang, Ruonan Lu, Jingyuan Wen, Wei Wu

{"title":"Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery.","authors":"Aun Raza, Runtong Zhang, Ruonan Lu, Jingyuan Wen, Wei Wu","doi":"10.1080/17435889.2025.2555507","DOIUrl":"10.1080/17435889.2025.2555507","url":null,"abstract":"Lipid nanoparticles (LNPs) enable RNA delivery, primarily via intramuscular (IM) injection, catalyzing breakthroughs like the Pfizer-BioNTech and Moderna COVID-19 vaccines. LNPs encapsulate RNA, using ionizable lipids for endosomal escape and PEG-lipids for stability. IM administration leverages muscle tissue's immune-rich environment, enabling localized antigen production, reduced systemic toxicity, and scalability. Challenges include cold-chain dependence, RNA instability, and immunogenicity from PEG/lipids. Future advancements, driven by AI (e.g. AGILE platform), hybrid lipid-polymer systems, and stimuli-responsive formulations, aim to enhance controlled release and stability. Innovations like thermostable lyophilized LNPs and biodegradable materials promise improved accessibility and safety. Beyond pandemics, LNPs hold potential for accelerating vaccines against HIV and malaria, and advancing personalized medicine through CRISPR therapies and cancer neoantigen vaccines. Interdisciplinary efforts in chemistry, immunology, and AI are poised to expand RNA therapeutics for genetic disorders, infectious diseases, and precision oncology. Evolving from emergency tools to mainstream platforms, LNPs herald a paradigm shift toward equitable access and tailored treatments for unmet clinical needs.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2545-2569"},"PeriodicalIF":3.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0